Plain-English translation of NCT07453927 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing blue light photobiomodulation therapy as an add-on to standard care for burn patients who have had skin grafting surgery. The blue light is delivered using an FDA-approved medical device called EmoLED, which has been used in clinical practice for wound healing. Researchers want to see if this treatment can speed up healing, reduce pain and swelling, and lower infection risk in the skin donation areas.
When doctors treat large burns with skin grafts, they have to harvest healthy skin from another part of the patient's body — the donor site. These donor areas are often slow to heal and can become painful, infected, or inflamed, which prolongs hospital stays and affects quality of life. This trial exists to see whether this treatment can help these donor sites heal faster and more comfortably.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either standard wound care alone, or standard wound care plus blue light therapy sessions on your donor sites. The blue light device will be applied to your healing wounds according to a treatment schedule. You will be monitored throughout your hospital stay and recovery to measure how well your wounds heal, track pain levels, check for infection, and assess overall safety and comfort.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
Italy